argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025 01:00 ET | Source: argenx SE June 3, 2025Amsterdam,…
KT&G Takes Legal Action Against Local Counterfeit Cigarette Manufacturers and Distributors in India
- Growing counterfeit cigarette manufacture and distribution leads to severe negative consequences…
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and…
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
April 27, 2025 10:35 ET | Source: SpringWorks Therapeutics, Inc. STAMFORD, Conn.,…
Education Cannot Wait Welcomes Sigrid Kaag of The Netherlands as New Chair of its High-Level Steering Group
The visionary advocate for children's rights will lead ECW's global efforts to mobilize…
European Commission Approves Pfizers RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European…
JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial
March 31, 2025 09:00 ET | Source: JenaValve Technology, Inc. IRVINE, Calif.…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Shepherd Partners with Intel to Enhance its Endpoint Protection Suite with Hardware-based Ransomware Detection
Shepherd, a leading IoT and enterprise endpoint security and management vendor headquartered…
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class…